MRK vs PETS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
PETS exhibits a stable Piotroski F-Score of 5/9, but this is overshadowed by catastrophic fundamental decay. The company is experiencing a severe collapse in profitability with an ROE of -100.61% and accelerating revenue declines (-21.7% YoY, -29.95% Q/Q). Despite a very low Debt/Equity ratio, the current ratio of 0.89 indicates immediate liquidity risks, while a 0/4 earnings beat record over the last year suggests a complete loss of operational control.
Compare Another Pair
Related Comparisons
MRK vs PETS: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and PetMed Express, Inc. (PETS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.